Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Jiangsu Hengrui Medicine Co., Ltd.
  6. News
  7. Summary
    600276   CNE0000014W7

JIANGSU HENGRUI MEDICINE CO., LTD.

(600276)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Jiangsu Hengrui Medicine Co., Ltd. Announces Approval of Conducting Clinical Trial in USA for Camrelizumab for Injection and Famectinib

03/11/2021 | 05:38am EDT

Jiangsu Hengrui Medicine Co., Ltd. announced Approval of Conducting Clinical Trial in USA for Camrelizumab for Injection and Famectinib.


© S&P Capital IQ 2021
All news about JIANGSU HENGRUI MEDICINE CO., LTD.
10/19Jiangsu Hengrui Medicine Co., Ltd. Reports Earnings Results for the Nine Months Ended S..
CI
08/26BeyondSpring Shares Up 17% After China Commercialization Deal
DJ
08/25Dalian Wanchun Brin Pharmaceutical Co., Ltd. announced that it expects to receive CNY 1..
CI
08/19Jiangsu Hengrui Medicine Co., Ltd. Reports Earnings Results for the Half Year Ended Jun..
CI
07/01MARKET CHATTER : China Adds New Drugs to Cover Under Health Insurance Program
MT
06/24China stocks slip as healthcare firms retreat; Hong Kong up
RE
05/21Jiangsu Hengrui Pharmaceuticals Co., Ltd. Announces on Obtaining Notice of Approval of ..
CI
05/03Shanghai Fosun Pharmaceutical's H-Shares Surge to All-Time High
DJ
04/19Jiangsu Hengrui Medicine Co., Ltd. Reports Earnings Results for the First Quarter Ended..
CI
03/15EXCLUSIVE : China's JD.com in talks to buy stake worth $1.5 billion in brokerage - sources
RE
More news
Financials
Sales 2021 28 650 M 4 489 M 4 489 M
Net income 2021 6 373 M 999 M 999 M
Net cash 2021 18 844 M 2 953 M 2 953 M
P/E ratio 2021 51,3x
Yield 2021 0,34%
Capitalization 327 B 51 202 M 51 224 M
EV / Sales 2021 10,8x
EV / Sales 2022 8,74x
Nbr of Employees 28 903
Free-Float 47,0%
Chart JIANGSU HENGRUI MEDICINE CO., LTD.
Duration : Period :
Jiangsu Hengrui Medicine Co., Ltd. Technical Analysis Chart | 600276 | CNE0000014W7 | MarketScreener
Technical analysis trends JIANGSU HENGRUI MEDICINE CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 24
Last Close Price 51,30 CNY
Average target price 72,08 CNY
Spread / Average Target 40,5%
EPS Revisions
Managers and Directors
Song Zhou Chief Financial Officer
Wei Dong Chairman-Supervisory Board
Piao Yang Sun Chairman
Shuang Xue Independent Director
Qian Wang Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JIANGSU HENGRUI MEDICINE CO., LTD.-44.77%50 337
JOHNSON & JOHNSON3.83%430 148
ROCHE HOLDING AG15.79%339 425
PFIZER, INC.16.27%240 303
NOVO NORDISK A/S56.55%239 079
ELI LILLY AND COMPANY42.84%218 640